UGT1A1 and Hyperbilirubinemia: Nilotinib is a common drug used in imatinib-resistant or imatinib-intolerant CML, and it is recommended to test for the genetic variant associated with nilotinib-induced hyperbilirubinemia, such as UGT1A1*28 and UGT1A1*6, ahead of nilotinib administration [23,24,25,26].